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Abstract
Background: The amyloid hypothesis in Alzheimer disease (AD) considers amyloid β peptide (Aβ) deposition
causative in triggering down-stream events like neurofibrillary tangles, cell loss, vascular damage and memory
decline. In the past years N-truncated Aβ peptides especially N-truncated pyroglutamate AβpE3-42 have been
extensively studied. Together with full-length Aβ1–42 and Aβ1–40, N-truncated AβpE3-42 and Aβ4–42 are major variants
in AD brain. Although Aβ4–42 has been known for a much longer time, there is a lack of studies addressing the
question whether AβpE3-42 or Aβ4–42 may precede the other in Alzheimer’s disease pathology.
Results: Using different Aβ antibodies specific for the different N-termini of N-truncated Aβ, we discovered that
Aβ4-x preceded AβpE3-x intraneuronal accumulation in a transgenic mouse model for AD prior to plaque formation.
The novel Aβ4-x immunoreactive antibody NT4X-167 detected high molecular weight aggregates derived from N-
truncated Aβ species. While NT4X-167 significantly rescued Aβ4–42 toxicity in vitro no beneficial effect was observed
against Aβ1–42 or AβpE3-42 toxicity. Phenylalanine at position four of Aβ was imperative for antibody binding,
because its replacement with alanine or proline completely prevented binding. Although amyloid plaques were
observed using NT4X-167 in 5XFAD transgenic mice, it barely reacted with plaques in the brain of sporadic AD
patients and familial cases with the Arctic, Swedish and the presenilin-1 PS1Δ9 mutation. A consistent staining was
observed in blood vessels in all AD cases with cerebral amyloid angiopathy. There was no cross-reactivity with
other aggregates typical for other common neurodegenerative diseases showing that NT4X-167 staining is specific
for AD.
Conclusions: Aβ4-x precedes AβpE3-x in the well accepted 5XFAD AD mouse model underlining the significance of
N-truncated species in AD pathology. NT4X-167 therefore is the first antibody reacting with Aβ4-x and represents a
novel tool in Alzheimer research.
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Background
Several hypotheses have been proposed and competed in
trying to explain the underlying cause of Alzheimer’s
disease (AD). The dominant hypothesis, since 1991, is
the amyloid hypothesis that implicates amyloid-β (Aβ)
deposits as the cause of this common neurodegenerative
disorder. Extracellular deposits of Aβ protein and the
intracellular accumulation of phosphorylated tau protein
are the basis of the neuropathological characterization of
AD [1-3]. Contemporary AD research has been driven
forward through the use of advanced molecular biology
tools. One key discovery, the isolation and sequencing of
the gene encoding the larger amyloid precursor protein
(APP) [4], was made possible by the biochemical analysis
of β-amyloid containing blood vessels (CAA, cerebral
amyloid angiopathy) [5] and amyloid plaques consisting
of Aβ [6].
The “Amyloid Hypothesis” was proposed, therefore,
based on the previously mentioned discovery [3,7]. Since
then, however, amyloid plaque load in the brain and cog-
nitive impairment in suffering patients [8] or even in
transgenic mouse models for AD [9,10] have not been
found to be consistently correlated. This gave rise to
considerable controversy in the field.
Memory loss in AD is the most prominent clinical
manifestation of the disease. To that end, Haass and
Selkoe [11] have recently evaluated the concept that sol-
uble oligomers of Aβ, acting as diffusible assemblies, are
capable of interfering with synaptic function and integ-
rity. This has provided a gateway for understanding the
basis of memory loss in AD. They debated that while in-
soluble plaque deposits might function as reservoirs of
the pathological oligomers, the small soluble oligomers
affect synaptic structure and plasticity. A modified amyl-
oid hypothesis was brought forth, wherein it has been
suggested that intraneuronal Aβ accumulation precedes
the extracellular formation of Aβ plaques and other AD
pathological events [12]. It is now well accepted that the
pathologically inert amyloid fibrils, which are found in
plaques, originate from a nearly irreversible reaction
driven by monomeric Aβ peptide through toxic proto-
fibrillar intermediates. For instance, the fact that amyloid
plaques possibly are major sources of soluble toxic Aβ-
aggregates that could readily be activated by exposure
to biological lipids, has been credibly demonstrated by
Martins et al. [13].
In addition to Aβ1 starting with aspartate as the first
amino acid, several N-truncated and modified Aβ
species have been characterized [14-16]. In fact, various
N- and C-terminal variants have been described in con-
junction with in vitro and in vivo analysis of amyloid de-
posits in AD [14,17,18]. The toxicity of Aβ was further
promoted due to enhanced aggregation and deposition
brought on by the increase in C-terminal length of Aβ
(from Aβx-40 to Aβx-42) and by N-terminal truncation
[19-21]. Among Aβ species present in AD plaques,
Lewis et al. [22] reported that Aβ4-42 is a relatively abun-
dant species in AD, aged controls and vascular dementia
patients.
Mori and colleagues discovered that approximately 15-
20% of Aβ peptides carried a pyroglutamate residue at
their N-terminus [23]. This ignited a spark of interest in
the temporal and spatial deposition of pyroglutamate
Aβ, which has increased ever since. For instance, Saido
et al. demonstrated by immunohistochemistry and bio-
chemical assays AβpE3-x is present in equivalent or larger
amounts than full-length Aβ in senile plaques. The
suggestion that AβpE3-x precedes the deposition of un-
modified Aβ (Aβ1-x) was also proposed by the authors
based on their analysis of brain tissue from Down syn-
drome cases [24]. Saido et al. furthermore suggested
that, due to their limited degradation, AβpE3 and other
modified Aβ species accumulate unhindered [16]. The
aggregation tendency and stability of the AβpE3-x pep-
tides is due to the formation of the lactam ring and loss
of two negative charges and one positive charge [16].
The stability of the peptide is further increased by the
formation of the moiety-terminal pyroglutamate that is
resistant to degradation by peptidases. He and Barrow
[19] reported that, as compared to full-length Aβ, AβpE3-x
peptides exhibited enhanced β-sheet formation and aggre-
gation propensity in aqueous and hydrophobic media.
They proposed that a reduction of the level of unfavorable
charge repulsion between strands, brought on by the loss
of the three charged groups, facilitates and stabilizes β-
sheet formation. Using immunoprecipitation in combin-
ation with mass spectrometry, Portelius and colleagues
[25] showed that Aβ1-40, Aβ1-42, pyroglutamate AβpE3-42
and Aβ4-42 can be detected in the hippocampus and cortex
of AD patients. Interestingly, it has been demonstrated
that N-terminal deletions enhance Aβ aggregation when
comparing Aβ4-42 with Aβ1-42 [21].
The weak correlation between the severity of dementia
and the density and localization of amyloid plaques in
the brain of AD patients is one of the major flaws in the
amyloid hypothesis. Even before the primary signs of
plaque deposition, memory impairment and pathological
changes already appear in many AD mouse models [26].
Soluble oligomers are low molecular weight non-fibrillar
structures, which are stable in aqueous solution and re-
main soluble even after high speed centrifugation [26].
Occurring more often than their proliferation inside the
extracellular space, Aβ oligomers develop preferentially
within neuronal processes and synapses [27,28]. Results
from several labs led to the proposition of these oligo-
mers as the missing link in the amyloid hypothesis.
While Aβ plaques are poor correlates for the clinical
symptomatology in AD and Down syndrome patients,
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soluble oligomers are suggested to be good predictors
for synaptic loss [29], neurofibrillary tangles [30] and
clinical phenotype [31,32]. Tomiyama et al. generated
APP transgenic mice expressing the E693Δ mutation,
which causes neuronal cell death and cognitive impair-
ment by enhanced intracellular Aβ oligomerization with-
out plaque formation [33].
Although Aβ4–42 is highly abundant in AD brains and
was the first N-truncated peptide discovered [14] its pos-
sible role in AD pathology has been largely overlooked. We
have recently shown that Aβ4–42 rapidly forms aggregates
and possesses a high aggregation propensity [34]. In vitro
and in vivo exposure indicated that Aβ4-42 is as toxic as
AβpE3-42 and Aβ1–42. In addition, we have generated trans-
genic mice expressing Aβ4-42 (Tg4-42 transgenic line) that
developed a massive CA1 pyramidal neuron loss in the
hippocampus [34]. Interestingly, as assessed using the
Morris water maze test, the hippocampus-specific expres-
sion of Aβ4–42 alone correlated with age-dependent spatial
reference memory deficits [34]. In the present report, we
developed a novel antibody specific for N-truncated Aβ
and characterized it using a toxicity assay, 5XFAD trans-
genic mice, sporadic and familial AD cases.
Methods
Generation of NT4X-167 antibody
The novel oligomeric Aβ specific antibody NT4X-167
(IgG2b; official name of cell line Aβ4–40 NT4X-167;
DSM ACC3162) was generated by immunizing three
Balb/c mice with unconjugated Aβ4–40. After preparation
of the lymph nodes they were fused with the myeloma
cell line P3-X63-Ag8 for generation of the hybridoma
cells. The hybridoma supernatants of mixed clones were
screened by ELISA and immunohistochemistry and
subcloned. The idea behind the generation of novel olig-
omeric antibodies was that in solution Aβ4–40 peptides
are forming stable aggregates that can be used as an epi-
tope for antibodies that specifically bind at the N-
terminus of Aβ4–40. Therefore Aβ4–40 was used for im-
munizing mice and positive clones screened in four
steps. After fusion, the hybridoma cells were screened by
an enzyme-linked immune-absorbent assay (ELISA) for
antibody production that (1) bind Aβ4–10 and (2) Aβ4–40,
but (3) not Aβ36–40. Positive antibody clones were fur-
ther screened by immunohistochemical staining of hu-
man brain sections. (4) The last step of the screening
procedure was that they should not preferentially bind
to amyloid plaques thereby identifying NT4X-167.
Electrophoresis and blotting of synthetic peptides
For Western blot analysis under reducing conditions,
peptides were loaded on 4-12% Tris-Tricin VarioGels
(Anamed), transferred to 0.45 μm nitrocellulose mem-
branes (GE Healthcare) and detected using the primary
antibodies IC16 (1 μg/ml), 1–57 (1 μg/ml) and NT4X-
167 (1 μg/ml). Blots were developed using Luminata
Crescendo Western HRP Substrate (Millipore) and ex-
posed with the ODYSSEY Fc (LI-COR).
For Western blotting under native conditions 4-16%
SERVAGel N native gels (Serva) were used under blue
native conditions. Running and transfer buffers were
applied according to the manufacturer instructions.
Nitrocellulose membranes (GE Healthcare) were de-
tected using the primary antibodies IC16 (1 mg/ml;
diluted 1:1000) (generous gift by Sascha Weggen [35]),
1–57 (1 mg/ml; diluted 1:500) [36] and NT4X-167 (1
mg/ml; diluted 1:300). Secondary antibodies were
rabbit-anti-mouse HRP-conjugated (Dianova). Blots
were developed using Luminata Crescendo Western
HRP Substrate (Millipore) and exposed with the
ODYSSEY Fc (LI-COR).
Monomerization of synthetic peptides
Stock solutions of synthetic peptides (1mg/ml in 10 mM
NaOH; PSL, Heidelberg) were prepared, sonicated for 5
min in water bath (Sonorex RK 100H, Bandelin elec-
tronic), quickly frozen in liquid nitrogen and stored
at −80°C.
Pepscan of synthetic peptides using ELISA
100 ng 16 amino acid long Aβ peptides (Aβ1–16, 2–17, 3–
18, 4–19, 5–20, 6–21, 7–22, 8–23, 9–24 and 10–25) were used.
The peptides were coated in a 96 well plate overnight
and reacted with NT4X-167 as primary antibody followed
by incubation with horse radish peroxidase conjugated
secondary antibodies (Dianova).
Neuronal culture
Cortical neurons from embryonic day 16–17 Wistar rat
fetuses were prepared as previously described [37]. In
brief, dissociated cortical cells were plated at 50,000
cells/well in 48-well plates precoated with 1.5 mg/mL
polyornithine (Sigma). Cells were cultured in a chem-
ically defined Dulbecco’s Modified Eagle’s/F12 medium
free of serum (Gibco) and supplemented with hormones,
proteins and salts. Cultures were kept at 35°C in a hu-
midified 5% CO2 atmosphere, and at 6–7 DIV, cortical
population was determined to be at least 97% neurons
by immunostaining as done previously [38]. At 6 DIV,
the medium was removed and cortical neurons were in-
cubated for 24 h with vehicle (cell culture medium) or
Aβ peptides (dissolved in cell culture medium) at the in-
dicated concentrations.
Cell viability measurement
Following a 24 h incubation of primary cortical neurons
with Aβ peptides, cell viability was determined using a
calcein-AM assay (Invitrogen, Molecular Probes). Briefly,
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cells were washed twice with PBS and incubated
protected from light for 30 min at room temperature in
the presence of 2 μM calcein-AM solution prepared in
PBS. Cells were then washed twice with PBS and incu-
bated for 15 min at room temperature in PBS containing
1% Triton X-100 (v/v). The level of calcein fluorescence
was monitored by fluorescence emission at 530 nm after
exciting at 485 nm, using a Fluostar microplate reader
(BMG-Labtechnologies, France).
Transgenic mouse brain samples
5XFAD mice express the 695 amino acids isoform of the
human amyloid precursor protein (APP695) carrying the
Swedish/London/Florida mutations under the control of
the murine Thy1-promoter [39]. In addition, human
presenilin-1 (PS1) carrying the M146L/L286V mutations
is expressed also under the control of the murine Thy1-
promoter. 5XFAD mice used in the current study were
backcrossed for more than eight generations to C57Bl/6J
wild-type mice to obtain an incipient congenic line on a
C57Bl/6J genetic background [40]. Homozygous 5XFAD
mice were verified by back-crossing to wildtype mice.
All animals were of male sex and handled according to
guidelines of the German animal protection law.
Human brain samples
Human brain samples were obtained from the Netherlands
Brain Bank (NBB), the Institute of Neurology, Medical
University of Vienna, Austria, Department of Pathology,
University of Helsinki, Finland and Department of Path-
ology, University of Uppsala, Sweden were approved by
the local Ethical Committees.
Immunohistochemistry of brain sections
Human and mouse tissue samples were processed as de-
scribed previously [36]. In brief, 4 μm paraffin sections
were pretreated with 0.3% H2O2 in PBS to block en-
dogenous peroxidases and antigen retrieval was achieved
by boiling sections in 0.01 M citrate buffer pH 6.0,
followed by 3 min incubation in 88% formic acid. Pri-
mary antibodies were incubated overnight, followed by
incubation with biotinylated secondary rabbit-anti-mouse
antibodies (DAKO) before staining was visualized using
the ABC method with Vectastain kit (Vector Labo-
ratories) and diaminobenzidine as chromogen. Primary
antibodies used were IC16 (against the N-terminus of
Aβ1-x 1 mg/ml; diluted 1:5000), 1–57 (against the N-
terminus of pyroglutamated Aβ3-x, 1 mg/ml; 1:5000) and
NT4X-167 (against the N-terminus of Aβ4-x; 2 mg/ml;
diluted 1:200).
Statistical analysis
Differences between groups were tested with one-way
analysis of variance (ANOVA) followed by Bonferroni
multiple comparison. All data are given as means ±
standard error of the mean (SEM). All statistics were
calculated using GraphPad Prism version 5.04 for Win-
dows (GraphPad Software, San Diego, California, USA)
and SPSS statistics version 17.0 (IBM, Armonk, New
York, USA).
Results
Specificity of NT4X-167 binding for Aβ under denaturing
conditions
Freshly dissolved Aβ peptides were subjected to SDS-
PAGE to dissect the binding specificity of the three
tested antibodies (Figure 1). Under denaturing condi-
tions NT4X-167 reacted with both N-terminally trun-
cated AβpE3-X and Aβ4-X variants, but not with Aβ1-X. In
addition to monomers and dimers, trimers and tetra-
mers of AβpE3-42 and Aβ4–42 were recognized. AβpE3-40
and Aβ4–40 produced primarily monomers and dimers.
Antibody 1–57 stained only AβpE3-40 and AβpE3-42, but
no other bands as previously demonstrated [36]. IC16
recognized the N-terminus of full-length Aβ1–40 and
Aβ1–42, but not any of the N-truncated peptides.
Specificity of NT4X-167 binding for Aβ under native
conditions
Under native conditions (Figure 2), freshly dissolved Aβ
peptides immediately formed high molecular weight ag-
gregates of different sizes. The binding specificity of the
three antibodies tested was the same as in the SDS
PAGE. IC16 was specific for the N-terminus of full-
length Aβ, but did not bind with any of the other N-
truncated peptides. 1–57 detected only AβpE3-40 and
AβpE3-42. NT4X-167 reacted with all four N-truncated
Aβ peptides AβpE3-40, AβpE3-42, Aβ4–40 and Aβ4–42. The
different Aβ variants produced distinct bands corre-
sponding to approximately: Aβ1–40 (20 and 30 kDa),
Aβ1–42 (20, 30 and 55 k Da as well as larger aggregates >70
kDa), AβpE3-40 (20, 30 and 50 kDa), AβpE3-42 (30, 50 and 55
kDa as well as larger aggregates >70 kDa). Interestingly,
Aβ4–40 and Aβ4–42 elicited only one band at approximately
50 kDa. The distinct band sizes are only an approximation
based on the migration of the protein ladder under native
conditions.
Epitope mapping using pepscan ELISA
Pepscan assays (Figure 3) were performed in order to
identify the binding epitope of NT4X-167 and IC16 to
the primary Aβ peptide sequences. The N-terminal bind-
ing specificity of 1–57 has already been published [36].
Pepscan ELISA for signal detection revealed that the
binding site of NT4X-167 ranged between N-truncated
Aβ2–4 with the highest signal for N-truncated Aβ4-x
starting with phenylalanine at position four, as compared
to IC16, which preferentially bound to positions 1–3 of
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Aβ. Mutational analysis of Aβ4–19 replacing phenyl-
alanine with alanine (Aβ4A-19) or proline (Aβ4P-19)
completely inhibited binding of NT4X-167 antibody.
Therefore, phenylalanine at position four of Aβ is the
essential amino acid required for NT4X-167 antibody
binding.
NT4X-167 detects Aβ4–42 in the low picomolar range
In order to analyze the sensitivity of NT4X-167, a dilu-
tion series was performed with freshly dissolved syn-
thetic Aβ4–42 and the staining was visualized using a
Western blot under reducing conditions (Additional file
1: Figure S1). NT4X-167 detected monomers and dimers
between 1 and 0.03 μg corresponding to a minimum of
approximately 7 picomoles of Aβ4–42.
NT4X-167 rescued Aβ4–42 in vitro
In vitro toxicity was studied in primary neurons using a
calcein assay. Treating the cells with freshly prepared
Aβ4-42, AβpE3-42 and Aβ1-42 resulted in a dose-dependent
reduction in cell viability (Figure 4) as previously shown
[34]. While NT4X-167 significantly rescued toxicity of
Aβ4-42, no effect was observed after AβpE3-42 or Aβ1-42
exposure. The in vitro toxicity assay provided compelling
evidence that NT4X-167 specifically protected against
Aβ4-42 and not with AβpE3-42 aggregates.
Figure 1 SDS-PAGE Western blot analysis of IC16, 1–57 and NT4X-167 antibodies. Freshly dissolved synthetic Aβ variants (7 μg each)
were probed to a membrane. (a) IC16 detects Aβ1–40 and Aβ1–42 monomers and low molecular weight aggregates. (b) 1–57 recognizes AβpE3-
40 and AβpE3-42 monomers, low molecular weight and larger aggregates of AβpE3-42. (c) NT4X-167 recognizes monomers and low molecular
weight aggregates derived from AβpE3-40, AβpE3-42, Aβ4–40 and Aβ4–42.
Figure 2 Western blot analysis of IC16, 1–57 and NT4X-167 antibodies under native conditions. Freshly dissolved synthetic Aβ variants (2
μg each) were probed to a membrane. (a) IC16 detects Aβ1–40 and Aβ1–42 monomers, low molecular weight oligomers and larger aggregates of
Aβ1–42. (b) 1–57 recognizes AβpE3-40 and AβpE3-42 monomers, low molecular weight oligomers and larger aggregates of AβpE3-42. (c) NT4X-167
recognizes monomers and aggregates derived from AβpE3-40, AβpE3-42, Aβ4–40 and Aβ4–42.
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NT4X-167 detected early intraneuronal Aβ accumulation
in 5XFAD transgenic mice
In order to compare the staining pattern of NT4X-167
(against Aβ4-x and pyroglutamate Aβ3-x), 1–57 (against
AβpE3-x), and IC16 (against Aβ1-x), hemizygous and homo-
zygous 5XFAD mice were studied using cortical sections,
as this is the brain area with known abundant intraneuronal
Aβ in this model [39,40]. Homozygous 5XFAD mice were
generated in order to observe an aggravated amyloid path-
ology at an earlier time point as compared to hemizygous
mice. As expected, intraneuronal Aβ1-x accumulation was
observed in young (Figure 5a and b), but not in aged
5XFAD mice (Figure 5c and d). Such transient appearance
of intraneuronal accumulation of Aβ peptides in young
APP transgenic has already been described earlier
[41]. Homozygous 6 week-old 5XFAD mice showed an
Figure 3 Phenylalanine at position four of Aβ is important for NT4X-167 binding. Pepscan analysis using ELISA of (a, c) NT4X-167 and (b)
IC16. Soluble synthetic Aβ peptides of 16 amino acids in length were probed and incubated with the antibodies. (a) NT4X-167 recognizes
N-terminal truncated Aβ peptides corresponding to positions 2–4 of Aβ. Peptides starting with phenylalanine (P; position 4 of Aβ) gives the
highest signal. No signal above background is seen in the absence of probed peptide and primary or secondary antibody. (b) IC16 binds to
peptides with N-terminal Aβ1–4 with a preference for position Aβ2. (c) NT4X-167 signal is completely abolished by replacing phenylalanine with
alanine (A) or proline (P) showing the importance of phenylalanine at position 4 for NT4X-167 binding. The signals of mutant peptides are at
background signals. Abbreviation: Ab, antibody.
Figure 4 Cellular toxicity of N-truncated Aβx-42 peptides and treatment effect of NT4X-167. In rat primary cortical neurons, all Aβx-42
peptides induce significant dose-dependent cellular toxicity. NT4X-167 treatment completely rescues toxic effects of freshly dissolved 1,
5 and 10 μM Aβ4–42, but not of AβpE3-42 or Aβ1–42 in vitro (ANOVA, P<0.0001, F= 87.24, dF=17). After ANOVA, the individual groups were
subsequently analyzed using Bonferroni multiple comparisons. Abbreviation: ****, P<0.0001.
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aggravated intraneuronal signal compared to hemizygous
mice (Figure 5a vs. 5b). Aged mice demonstrated abun-
dant Aβ1-x accumulation in amyloid plaques (Figure 5c
and d). NT4X-167 recognized intraneuronal Aβ in 6
week-old homozygous 5XFAD mice (Figure 5f), a signal
absent with the AβpE3-x specific antibody 1–57 (Figure 5j).
Therefore the signal was due to Aβ4-x accumulation,
which represents the earliest N-truncated Aβ species. In
fact, using 1–57, we did not see any intraneuronal signal
at any ages analyzed. Amyloid plaques were detected with
both NT4X-167 and 1–57 in aged mice (Figure 5g-h, k-l).
NT4X-167 demonstrated a minor plaque binding activity
in sporadic and familial Alzheimer’s disease
In order to characterize the staining pattern of the
NT4X-167 in AD patients, cortical tissue sections
with sporadic (Table 1, Figure 6) and familial AD
(Table 2, Figure 7) were analyzed. Compared to the
IC16, NT4X-167 recognized only a minor portion of
plaques in brain tissue of AD patients. Cerebral
amyloid angiopathy (CAA) staining of blood vessel
walls was seen with both antibodies. In familial AD
cases, NT4X-167 positive plaques were almost absent
in patients with a mutation in presenilin-1 gene
(PS1Δ9; [42]), and much weaker in cases with the
Arctic [43,44] or Swedish [45] APP mutation compared
to IC16 staining.
NT4X-167 did not cross-react with other major
proteinopathies
In order to study a potential cross-reactivity with other
disease-typical aggregates, brain tissue sections were
stained with disease-specific markers and compared with
NT4X-167 reactivity. NT4X-167 did not cross-react
with other aggregated deposits of non-AD neurode-
generative disorders. The following pathological struc-
tures showed no immunoreactivity (Table 3; Figure 8):
(i) Phospho-Tau immunoreactive structures, including
tufted astrocytes in progressive supranuclear palsy
(PSP) and Pick bodies in Pick’s disease (PiD). (ii) α-
Figure 5 Immunohistochemical staining of cortical sections of 5XFAD transgenic mice. (a) Immunostaining with IC16 demonstrating
intraneuronal Aβ accumulation in 6 week old hemizygous 5XFAD. (b) Homozygous 5XFAD mice exhibited more intensive intraneuronal staining
at the same age. (c, d) Abundant extracellular plaque staining with IC16 at the age of 12 months. (e) No signal was detected using NT4X-167 in 6
week old hemizygous 5XFAD. (f) In homozygous 5XFAD mice significant intraneuronal staining was observed with NT4X-167. (g, h) Abundant
extracellular plaque staining with NT4X-167 at the age of 12 months. (i, j) No intraneuronal Aβ was observed with the pyroglutamate specific
antibody 1–57 in 6 week-old hemizygous (i) and homozygous (j) 5XFAD mice. (k, l) Extracellular plaque staining with 1–57 at the age of 12
months. At 12 months only hemizygous 5XFAD are used. Abbreviations: w, week; m, month. Scale bar in k for a-c, e-g and i-k: 50 μm, and in
l for d, h and l: 200 μm.
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Synuclein immunopositive Lewy bodies (brainstem and
cortex) and Lewy neurites in Parkinson’s disease (PD)
and dementia with Lewy bodies (DLB), and glial cyto-
plasmic inclusions in multiple system atrophy (MSA).
(iii) Phospho-TDP-43 immunoreactive neuronal cyto-
plasmic and neuritic deposits in frontotemporal lobar
degeneration with TDP-43 pathology (FTLD-TDP),
amyothrophic lateral sclerosis (ALS), and AD with limbic
TDP-43 deposits. (iv) Prion protein (PrP) immunopositive
amyloid plaques, synaptic, plaque-like, and perineuronal
deposits. In addition, there was no immunoreactivity asso-
ciated with small vessel disease in Binswanger disease.
Discussion
The amyloid-β hypothesis has been the most influential
hypothesis in coining the molecular pathology of AD [2].
According to the initial hypothesis, amyloid fibrils,
which are large insoluble polymers of Aβ found in senile
plaques, are the major trigger of neuron loss and demen-
tia that are typical for AD. While Aβ plaques are poor
correlates for the clinical symptomatology in AD and
Down syndrome patients, soluble oligomers are sug-
gested to be good predictors for synaptic loss [29],
neurofibrillary tangles [30] and clinical phenotype [46].
Furthermore, memory impairment and pathological changes
in many AD mouse models occur well before the onset of
plaque deposition [47]. Albeit there are convincing genetic,
biochemical and cell biological data pointing to a major role
of Aβ in AD, growing evidence points towards soluble Aβ
oligomers rather than Aβ precipitated in plaques. Blennow
et al. [48] for example discussed whether Aβ deposition is the
cause or consequence of neurodegeneration in sporadic AD,
Table 1 List of demographic data of sporadic AD patients and non-demented controls and the staining profile
of the antibodies
No Age Mean±SEM Sex M/F Braak stage ApoE4 Plaques (IC16) CAA (IC16) Plaques (NT4X-167) CAA (NT4X-167)
Sporadic AD 13 76 ± 3 3/10 4-6 7/13 13/13 13/13 3/13 13/13
Controls 10 80 ± 2 6/4 0-1 2/10 5/10 3/10 0/10 3/10
Of note, none of the controls showed NT4X-167 staining of plaques although 5 of them were positive with IC16, demonstrating a clear difference between AD
and control cases. The amount of NT4X-167-positive plaques in sporadic AD brain was low.
Abbreviations: No number of cases, M male, F female, ApoE4 number of cases with at least one ApoE4 allele, CAA cerebral amyloid angiopathy.
Figure 6 Immunohistochemical staining pattern in superior temporal gyrus of a sporadic AD brain. (a-c) IC16 antibody visualized cerebral
amyloid angiopathy (CAA) and plaques. (d-f) Staining of parallel sections shows that NT4X-167 recognized preferentially CAA rather than plaques.
Scale bar: a, d: 200 μm and b, c, e, f: 50 μm.
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but also whether the transgenic mouse models are at
all accurate models for sporadic AD.
Soluble oligomers are low molecular weight non-
fibrillar structures, which are stable in aqueous solution
and remain soluble even after high speed centrifugation.
Aβ oligomers develop preferentially within neuronal
processes and synapses rather than in the extracellular
space [27,28]. At high concentrations, vesicular full-
length Aβ aggregates form high molecular weight oligo-
mers which are capable of seeding amyloid fibril growth
[49]. Results from several labs propose these oligomers
to be the missing link in the amyloid hypothesis. Just like
in the human brain, studies using AD mouse models
support the pathogenic role of oligomers. In the Tg2576
mouse model, the appearance of Aβ dodecamers coin-
cided with the onset of spatial memory impairment.
Interestingly, injection of these purified oligomers into
the ventricle of wildtype rats caused a dramatic drop in
spatial memory performance [50]. With regard to short-
term effects, oligomers have been shown to impair syn-
aptic plasticity by blocking long term potentiation and
reinforcing long term depression [51]. Another hint was
reported by Tomiyama et al. [33], who generated APP
transgenic mice expressing the E693Δ mutation causing
Table 2 List of the demographic data and staining profile of the antibodies in familial AD patients
Gene Mutation Sex Age Plaques (IC16) CAA (IC16) Plaques (NT4X-167) CAA (NT4X-167)
APP Arctic M 64 + + + +
Swedish F 61 + + + +
PS1 PS1Δ9 M 61 + + + +
M 64 + + + +
M 69 + + + +
NT4X-167 showed only CAA but almost no plaques in PS1Δ9 patients, while both CAA and plaques were observable in patients with Arctic and Swedish mutations
in the APP gene.
Abbreviations: M male, F female, CAA cerebral amyloid angiopathy.
Figure 7 Immunohistochemical staining of cerebral cortex in patients with familial AD. (a-c) using IC16 antibody and (d-f) parallel sections
using NT4X-167 antibody. (a, d) The patient harboring the Arctic mutation elicited positive blood vessels (CAA) and plaques with both antibodies,
staining in plaques being less pronounced with NT4X-167. (b, e) The patient with the Swedish mutation also demonstrated positive blood vessels
and plaques with both antibodies and again with a weaker staining in plaques with NT4X-167. (c, f) In the patient with the PS1 mutation ΔExon9,
positive blood vessels and plaques were seen with both antibodies again with a less pronounced staining in plaques with NT4X-167. Scale bar:
200 μm.
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neuronal cell death and cognitive impairment by en-
hanced intracellular Aβ oligomerization without plaque
formation. Loss of Aβ clearance instead of increased Aβ
generation has been considered to be involved in the
pathology of the sporadic variant of AD [52]. The above
mentioned thoughts consider full-length Aβ1–40/1–42 as
the major culprit in AD pathology.
Of note, full-length Aβ peptides are physiological mol-
ecules produced throughout the life of a human being.
The generation of N-truncated Aβ peptides has been
suggested to increase toxicity [53]. Pike et al. [21] com-
pared Aβ peptides with initial residues at positions 1, 4,
8, 12, and 17 and ending with residue 40 or 42 and
showed that N-terminal deletions enhance Aβ aggrega-
tion in relation to full-length Aβ. Furthermore they
reported that Aβ peptides exhibiting aggregation showed
circular dichroism spectra consistent with predominant
β-sheet conformation, fibrillar morphology under trans-
mission electron microscopy, and significant toxicity in
cultures of rat hippocampal neurons.
We have recently extended these observations and
showed that soluble aggregates have specific features re-
sponsible for their neurotoxicity [34]. Aβ4-40, Aβ4-42,
Aβ1-42 and AβpE3-42 were unstructured in the mono-
meric state [34]. However, upon heating the Aβ variants
showed a high propensity to form folded structures, in
particular the three most toxic variants AβpE3-42, Aβ1-42
and Aβ4-42. In addition, monomeric Aβ4-42 and AβpE3-42
were rapidly converted to soluble aggregated species.
Both N-truncated variants exhibited similar biochemical
properties, which opens the discussion which one of
them might be more important in AD pathology [34].
In the present report we endeavored to address this
question. We succeeded to develop an antibody differen-
tiating between full-length Aβ and the two other major
N-truncated variants, Aβ4-x and AβpE3-x. In combination
with two other antibodies exclusively reacting with Aβ1-x
(IC16) or AβpE3-x (1–57), we were able to show that
Aβ4-x preceded AβpE3-x accumulation in the brain of
5XFAD transgenic mice. More importantly, Aβ4-x was
detected together with Aβ1-x in the intraneuronal com-
partment of cortical neurons prone to degenerate in
5XFAD mice at 12 months of age [39,40]. Early and
transient intraneuronal accumulation of Aβ correlated
with subsequent neuron loss also in diverse APP/Aβ trans-
genic mouse models and brain regions [34,41,54-57]. Inter-
estingly, such a transient appearance of intraneuronal Aβx-
42 has also been described by Mori et al. [58] studying the
brain of Down syndrome patients between 3 to 73 years.
Using an antibody against the N-terminus of AβpE3-x, no
intraneuronal staining was reported [58] corroborating our
observation of a lack of intraneuronal accumulation of
AβpE3-x in 6 week-old 5XFAD mice in the present study.
Using an in vitro toxicity assay, we were able to dem-
onstrate that NT4X-167 is particularly protecting against
Aβ4–42 and that the binding to AβpE3-42 has no thera-
peutic consequence. The mechanism(s) of the diverging
biological effects are not clear. The Western blot analysis
might not accurately reflect the difference in affinity of
NT4X-167 between Aβ4–42 and AβpE3-42. The data from
the in vitro toxicity assay provides evidence that NT4X-
167 preferentially binds Aβ4–42. On the other side it
could also be that NT4X-167 does not efficiently bind to
some toxic aggregate(s) of AβpE3-42 as it did not signifi-
cantly detect the aggregate at 50 kDa as compared to 1–
57 antibody under native conditions. We have previously
shown that passive immunization of 5XFAD mice with
9D5, a monoclonal antibody specifically detecting low
molecular weight AβpE3-x aggregates, significantly re-
duced overall Aβ plaque load and AβpE3-x levels, and
normalized behavioral deficits [59].
While amyloid plaques were observed using NT4X-167
in 5XFAD transgenic mice, it barely reacted with plaques in
the brain of sporadic AD patients and familial cases with
the Arctic, Swedish and the presenilin-1 mutation PS1Δ9.
These data are corroborated by a previous work by Kuo
et al. [60]. They analyzed Aβ pathology using chemical
and morphological approaches comparing the plaques of
Table 3 Demographic data and examined anatomical regions from other neurodegenerative disorders cases
No Case/Disease Age Sex Examined regions
1 DLB 81 F Temporal Cx
2 PD 62 M Mesencephalon (SN)
3 MSA 52 M Pons
4 PSP 69 M Basal Ganglia
5 PiD 70 F Hippocampus + Ent Ctx + Temp Ctx
6 FTLD 62 F Hippocampus + Ent Ctx + Temp Ctx
7 CJD 72 F Hippocampus + Ent Ctx + Temp Ctx + Cbll
8 Binswanger disease 49 F Basal Ganglia
Abbreviations: DLB dementia with Lewy bodies, PD Parkinson’s disease, MSA multiple system atrophy, PSP progressive supranuclear palsy, PiD Pick’s disease, FTLD
frontotemporal lobar degeneration, CJD Creutzfeldt-Jakob disease, M male, F female, Ent Cx entorhinal cortex, Temp Ctx temporal cortex, SN substantia nigra, Cbll
cerebellum.
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APP23 transgenic mice and human AD brain. The authors
concluded that despite an apparent overall structural re-
semblance to AD pathology, the chemical analyses revealed
that the amyloid plaque cores in APP23 transgenic mice
were completely soluble in buffers containing SDS [60].
Human AD plaque cores were highly resistant to chemical
and physical disruption accounting for the extreme stability
of AD plaque cores [60]. Moreover, the corresponding lack
of post-translational modifications such as N-terminal deg-
radation, isomerization, racemization, pyroglutamyl forma-
tion, oxidation, and covalently linked dimers in transgenic
mouse Aβ, provides an explanation for the differences in
Figure 8 NTX4-167 showed no cross-reactivity with diagnostic aggregates in other major neurodegenerative diseases. Lower panels
represent parallel sections stained with NT4X-167. (a-c) Alpha-synuclein (α-syn) positive aggregates in Lewy bodies and Lewy neurites in
dementia with Lewy bodies and Parkinson disease and glial inclusions in multiple system atrophy. (d) Pathological vessels in Binswanger
encephalopathy (subcortical arteriolosclerotic encephalopathy). (e) Phospho-TDP-43 immunoreactive neuronal cytoplasmic inclusions in a patient
with frontotemporal lobar degeneration. (f-g) Phospho-tau (pTau) immunoreactive aggregates in progressive supranuclear palsy and in Pick’s
disease. (h) Prion protein (PrP) immunopositive synaptic deposits in sporadic Creutzfeldt-Jakob disease. Scale bar in a-f 50 μm, g-h, 200 μm.
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solubility between human AD and the APP23 mouse
plaques [60]. NT4X-167 preferably stained Aβ in blood
vessels in human specimens, in which Aβx-40 is a major
component. The Aβ plaques in PS1Δ9 AD cases are char-
acterized by cotton wool morphology composed by Aβx-42
aggregates. The lack of cotton wool plaque staining using
NT4X-167 further strengthens the possibility that it may
prefer binding to Aβ4-40 as compared to Aβ4-42 aggregates.
Selkoe and others reported that toxic Aβ oligomers
are primarily dimers and trimers of Aβ [28,61,62]. Haass
and Selkoe argued that small molecules that can specif-
ically inhibit the formation of Aβ oligomers and/or pre-
vent their binding to and stabilization on neuronal
membranes is at the top in the search for an AD therapy
[11]. More recently, De Strooper [63] discussed that it is
more likely that several of the identified oligomeric spe-
cies (derived from full-length Aβ) have similar or over-
lapping properties. They conclude that coexistence of
several oligomeric populations that do or do not propa-
gate into fibrils is possible. Despite the differences in
structure, stability and concentration, all oligomers may
contribute to Aβ toxicity. They further discussed some
technical issues defining oligomers like the apparent
‘SDS resistance’ [63]. Bitan et al. [64] have demonstrated
that SDS can artificially induce oligomerization of Aβ.
Hepler et al. [65] were able to isolate monomers, trimers
and tetramers as major bands derived from full-length
Aβ oligomers, Aβ fibrils and Aβ monomers after SDS-
PAGE separation. Our data are well in line with these
previous observations. Under reducing conditions AβpE3-
40 and Aβ4–40 generated monomers and dimers, while
AβpE3-42 and Aβ4–42 in addition produced trimers and
tetramers as previously shown [14,59]. Using native con-
ditions, Aβ1–42 and AβpE3-42 appeared as aggregates of
different sizes with higher molecular weight aggregates.
In contrast Aβ4–40 and Aβ4–42 ran as a single band at
approx. 50 kDa.
In fact, analysis of amyloid deposits in AD brains re-
vealed various N- and C-terminal variants [14,17,18].
The increased C-terminal length of Aβ (from Aβx-40 to
Aβx-42) enhances its aggregation properties. Faster aggre-
gation leads to earlier Aβ deposition, which is believed
to promote its toxicity [20,21,66]. Recently, Aβ1-43 was
discovered as a novel toxic peptide in AD [67,68]. Be-
sides Aβ peptides starting with aspartate as the first
amino acid (Aβ1), several N-truncated and modified Aβ
species have also been described [14-16,69]. Aβ4–42 be-
ing one of them is particularly interesting as its discov-
ery dates back to 1985 by Masters et al. [14]. Lewis et al.
[22] reported that Aβ4-42 is a relatively abundant species
in AD, aged controls and vascular dementia patients.
Using immunoprecipitation in combination with mass
spectrometry, Portelius and colleagues [25] showed that
Aβ1-40, Aβ1-42, AβpE3-42 and Aβ4-42 can be detected in
the hippocampus and cortex of AD patients. Moreover,
it has been demonstrated that N-terminal deletions en-
hance Aβ aggregation comparing Aβ4-42 with Aβ1-42
[21]. Youssef et al. [38] showed that Aβ1-42 and AβpE3-42
exhibited similar effects on neuronal cytotoxicity in primary
cortical neurons and on memory impairment after intra-
cerebroventricular injection in wildtype mice. AβpE3-42 is
now an established factor contributing to AD pathology
[53] and may even be aggravating the severity of the disease
[70]. Sergeant et al. demonstrated that amino-truncated Aβ
species represented more than 60% of all Aβ species, not
only in full blown AD, but also, and more interestingly, at
the earliest stage of AD pathology [71]. They concluded,
that a vaccine specifically targeting these pathological
amino-truncated species of Aβx-42 are likely to be promis-
ing, by inducing the production of specific antibodies
against pathological Aβ products that are, in addition, in-
volved in the early and basic mechanisms of amyloidosis in
the human brain.
The importance of position four of Aβ is corroborated by
Haupt et al. [72], who observed an N-terminal β-strand,
previously assumed to be an unstructured region [73-77].
Using proline mutagenesis to probe the structural relevance
of N-terminal residues, they demonstrated that mutations
affecting residues 4 or 8, significantly increased the fraction
of elongated aggregates indicating that disrupting the N-
terminal β-strand favors protofibrils relative to oligomers
[72]. The pathological impact of Aβ4–42 is elucidated by the
generation of transgenic mice (Tg4-42) expressing Aβ4–42
[34]. The Tg4-42 mice develop a severe age-dependent
spatial reference memory deficit and massive hippocampus
neuron loss.
At present, the enzymes responsible for N-terminal
truncation are not well studied. Aminopeptidase A
contributes to the N-terminal truncation of Aβ peptide
producing Aβ2-x [78]. Saido et al. [16] suggested that
mono- or dipeptidylaminopeptidases cleave Aβ1-x pro-
ducing N-terminal truncated Aβ3-x. AβpE3-x formation
is catalyzed by glutaminyl cyclase [79-82]. Which en-
zymes are involved in the truncation steps to generate
Aβ3-x and Aβ4-x is unknown.
Conclusion
The present report describes the binding properties of
the novel antibody NT4X-167, which recognizes the N-
terminus of N-truncated Aβ. NT4X-167 bound most ef-
ficiently to Aβ4-x. Phenylalanine at position four of Aβ
was imperative for NT4X-167 binding. In vitro toxicity
experiments demonstrated that Aβ4–42 induced neuron
death was significantly rescued by NT4X-167 treatment.
No rescue effect was observed for Aβ1–42 or AβpE3-42
toxicity. NT4X-167 detected only a minor fraction of
plaques in brain from sporadic and familial AD patients
and 5XFAD transgenic mice. It preferentially reacted
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with intraneuronal Aβ in young 5XFAD mice. The find-
ing that Aβ4-x precedes AβpE3-x in the well accepted
5XFAD AD mouse model further underlines the signifi-
cance of Aβ4-x. NT4X-167 did not cross-react with ag-
gregates typical for other major neurodegenerative
disorders implicating that the recognized aggregates are
specific for AD. Taking all observations together, NT4X-
167 represents a novel tool for AD research and therapy.
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